Named Bioactive Compounds · Compound
Canthaxanthin
Moderate Evidencecompound
Hermetica Superfood Encyclopedia
Canthaxanthin is a keto-carotenoid pigment (4,4'-diketo-beta-carotene) found naturally in mushrooms, crustaceans, and flamingo feathers, and used synthetically as a tanning supplement and food colorant. Its primary mechanism involves quenching singlet oxygen and free radicals via its extended conjugated polyene chain with two keto groups, though no clinical health benefits have been established in human trials.
Canthaxanthin is a naturally occurring keto-carotenoid pigment (C₄₀H₅₂O₂) found in edible mushrooms, green algae, bacteria, and crustaceans, bioaccumulating in fish like carp and seabream. It can be produced naturally through biosynthesis from isoprenoid precursors or synthetically via oxidation of β-carotene, and belongs to the chemical class of symmetrical ketocarotenoids.
The research dossier reveals no human clinical trials, randomized controlled trials, or meta-analyses have been conducted on canthaxanthin supplementation. No PubMed PMIDs or clinical study details are available in the current scientific literature.
No clinically studied dosage ranges have been established for canthaxanthin in any form (extract, powder, or standardized preparations). Consult a healthcare provider before starting any new supplement.
Canthaxanthin (β,β-carotene-4,4'-dione; C₄₀H₅₂O₂; MW 564.84 g/mol) is a diketo-carotenoid pigment, not a traditional food with a macronutrient profile. Key details: • Classified as a xanthophyll carotenoid with two conjugated carbonyl groups on the β-ionone rings and a polyene chain of 13 conjugated double bonds. • Unlike β-carotene, canthaxanthin has negligible provitamin A activity (<5% conversion efficiency relative to β-carotene) due to the 4,4'-diketo substitution blocking retinal cleavage. • Bioactive compound concentration: typically supplied as 10% formulations (beadlets or suspensions) for industrial use; pure compound is a dark violet crystalline powder. • No significant vitamins, minerals, fiber, or protein content — it is a single lipophilic compound. • Antioxidant capacity: singlet oxygen quenching rate constant ~1.0 × 10¹⁰ M⁻¹s⁻¹ (comparable to astaxanthin), peroxyl radical scavenging activity documented in vitro. • Bioavailability: highly lipophilic (logP ~12–14); oral absorption requires co-ingestion with dietary fat; absorbed via chylomicron pathway in the small intestine; peak plasma concentrations typically 0.1–0.5 µmol/L after repeated supplemental doses of 15–30 mg/day. • Tissue distribution: accumulates preferentially in adipose tissue, liver, and retina; at high chronic doses (≥30 mg/day), characteristic crystalline deposits (canthaxanthin retinopathy) form in the paramacular retina. • Dietary sources providing trace amounts (<0.1–2 mg/serving): chanterelle mushrooms (Cantharellus cibarius, ~0.01–0.1 mg/100 g), certain crustacean shells, flamingo feathers (non-dietary), and farmed salmonid fish flesh where it is used as a feed additive (typically 5–25 mg/kg feed yielding ~1–8 mg/kg flesh). • EU-approved food colorant (E161g) with ADI set at 0.03 mg/kg body weight/day (EFSA, 2010); FDA permits use only in animal feed (poultry), not as a direct human food additive. • Metabolites: partially converted to 4-oxo-retinoic acid and other apo-carotenals in vivo, though metabolic pathways are incompletely characterized. • No essential nutrient status; no RDA, AI, or DRI established for canthaxanthin.
Canthaxanthin exerts antioxidant activity through its conjugated polyene backbone containing 11 conjugated double bonds and two flanking keto groups at the 4 and 4' positions, which facilitate efficient singlet oxygen quenching and free radical scavenging via electron delocalization. As a carotenoid, it may interact with lipid bilayers in cell membranes, potentially modulating lipid peroxidation cascades involving reactive oxygen species. Unlike beta-carotene, canthaxanthin is not a provitamin A precursor and does not bind retinoid receptors (RAR/RXR), limiting its functional overlap with other carotenoids at the receptor level.
No controlled human clinical trials have been published establishing therapeutic health benefits for canthaxanthin supplementation. The primary documented human data comes from pharmacokinetic and safety studies conducted in the context of its use as an oral tanning agent ('Orobronze'), where doses of 30–120 mg/day caused retinal crystal deposition (canthaxanthin retinopathy) in a significant proportion of users. A case series and observational data from dermatology literature documented reversible but concerning crystalline maculopathy in individuals consuming high cumulative doses exceeding 37 grams over time. The overall evidence base is insufficient to support any health claims, and current regulatory bodies, including the EU and FDA, have restricted or banned its use as an oral tanning supplement.
The most significant documented safety concern is canthaxanthin retinopathy, a condition characterized by gold-colored crystalline deposits in the retina observed at cumulative doses above approximately 37 grams, which may persist for years after discontinuation. High-dose supplementation (30–120 mg/day) has been associated with aplastic anemia in rare case reports, though causality is not firmly established. No well-characterized drug-drug interactions are formally documented, but as a fat-soluble carotenoid, canthaxanthin may compete with absorption of other fat-soluble nutrients including vitamins A, D, E, and K when taken with lipid-lowering agents like orlistat. Canthaxanthin is not recommended during pregnancy or breastfeeding due to the absence of safety data and its historical withdrawal from tanning markets on safety grounds.
